{
    "clinical_study": {
        "@rank": "151368", 
        "acronym": "PRECISION-F", 
        "arm_group": {
            "arm_group_label": "Sequencing of a metastatic lesion.", 
            "arm_group_type": "Other", 
            "description": "Biopsy of a metastatic lesion followed by a targeted cancer gene screen."
        }, 
        "brief_summary": {
            "textblock": "Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential\n      for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by\n      examining the feasibility and turnaround time of performing and obtaining data from a few\n      key molecular assays.\n\n      Patients with metastatic colorectal cancer, non-small cell lung cancer or melanoma will be\n      enrolled. Biopsie from metastatic lesions will be performed. A targeted cancer gene screen\n      assay will be performed using DNA sequencing.\n\n      Results will be discussed during a molecular screening tumor board."
        }, 
        "brief_title": "The Jules Bordet Institute Molecular Profiling Program Feasibility Trial", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastic Colorectal Cancer.", 
            "Metastatic Melanoma.", 
            "Metastatic Non-small Cell Lung Cancer."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Colorectal Neoplasms", 
                "Lung Neoplasms", 
                "Melanoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent for all study procedures according to local regulatory\n             requirements prior to enrollment into the study.\n\n          -  Age \u2265 18 years.\n\n          -  Histologically proven metastatic or locally recurrent CRC, NSCLC or melanoma.\n\n          -  Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for\n             research purposes.\n\n        Exclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status >2.\n\n          -  The biopsy procedure is estimated to be too risky for the patient.\n\n          -  Any anti-VEGF or anti-VEGFR treatment administered less than 3 weeks before new\n             biopsy procedure.\n\n          -  No appropriate washout period for patients on anticoagulation therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932489", 
            "org_study_id": "IJBCE2139"
        }, 
        "intervention": {
            "arm_group_label": "Sequencing of a metastatic lesion.", 
            "intervention_name": "Biopsy of a metastatic lesion.", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "philippe.aftimos@bordet.be", 
                "last_name": "Philippe G. Aftimos, M.D.", 
                "phone": "+3225413200"
            }, 
            "contact_backup": {
                "email": "maureen.billiet@bordet.be", 
                "last_name": "Maureen Billiet", 
                "phone": "+3225413200"
            }, 
            "facility": {
                "address": {
                    "city": "Brussels", 
                    "country": "Belgium", 
                    "zip": "1000"
                }, 
                "name": "Jules Bordet Institute"
            }, 
            "investigator": {
                "last_name": "Martine Piccart, M.D., PhD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "THE JULES BORDET INSTITUTE PROGRAM FOR MOLECULAR PROFILING OF METASTATIC LESIONS: FEASIBILITY. PRECISION - Feasibility.", 
        "overall_contact": {
            "email": "philippe.aftimos@bordet.be", 
            "last_name": "Philippe G. Aftimos, M.D.", 
            "phone": "+3225413200"
        }, 
        "overall_contact_backup": {
            "email": "maureen.billiet@bordet.be", 
            "last_name": "Maureen Billiet", 
            "phone": "+3225413200"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Jules Bordet Ethics Committee.", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Percentage of frozen and FFPE core biopsies that are able to provide at least 1.5 \u03bcg of DNA of high quality suitable for molecular testing.", 
                "measure": "Quality of the biopsies", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Frequency of failures of each pathological and molecular tests.", 
                "measure": "Technical failure rate.", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Percentage of patients for whom biopsy was performed within 10 working days from signature of the ICF and for whom all central laboratory results (pathology and molecular) will be available to the investigator within 15 working days from the time samples are received at the central laboratory (JBI).", 
                "measure": "Percentage of patients with results within the specified turnaround time", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932489"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Ability of the \"tumor sequencing board\" to assign patients to ongoing clinical trials.", 
            "measure": "Feasibility of a tumor sequencing board.", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "Jules Bordet Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jules Bordet Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}